Business Context and Reporting Period
This Form 8-K reports on the 2018 Annual Meeting of Shareholders held by Collegium Pharmaceutical, Inc. on May 24, 2018. The company is incorporated in Virginia and is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (April 4, 2018), 33,027,579 shares were entitled to vote, with 30,546,107 shares present in person or by proxy. The voting outcomes were as follows:
- Proposal 1 (Election of Class III Directors):
- Garen G. Bohlin: Elected with 17,191,901 votes For, 9,729,371 Against, and 30,148 Abstentions.
- Gwen A. Melincoff: Elected with 26,885,416 votes For, 35,906 Against, and 30,098 Abstentions.
- Theodore R. Schroeder: Elected with 17,161,307 votes For, 9,760,015 Against, and 30,098 Abstentions.
- Proposal 2 (Ratification of Auditors): Deloitte & Touche LLP was ratified with 30,504,826 votes For, 5,236 Against, and 36,045 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the significant opposition votes (approximately 9.7 million) cast against directors Garen G. Bohlin and Theodore R. Schroeder.
- Confirm the total number of broker non-votes (3,594,687) which did not affect the outcome of the director elections but indicate broker discretion.
- Review the company's proxy statement for context regarding the specific issues driving the dissenting votes for Proposal 1.